<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31891">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02047318</url>
  </required_header>
  <id_info>
    <org_study_id>LUM001-303</org_study_id>
    <nct_id>NCT02047318</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome</brief_title>
  <acronym>IMAGINE</acronym>
  <official_title>A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumena Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Childhood Liver Disease Research and Education Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lumena Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, extension study of LUM001 in children diagnosed with Alagille
      Syndrome who have completed participation in a core LUM001 treatment protocol. The primary
      objective is to evaluate long-term safety and tolerability of LUM001.  Efficacy will be
      assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus
      associated with Alagille Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, changes in vital signs, laboratory and other safety parameters from baseline to week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in serum bile acids, pruritus, and other biochemical markers of cholestasis and liver disease from baseline to week 48</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Alagille Syndrome</condition>
  <arm_group>
    <arm_group_label>LUM001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUM001 administered orally once each day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LUM001</intervention_name>
    <arm_group_label>LUM001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completed a core treatment protocol of LUM001 in the treatment of cholestatic liver
             disease in pediatric subjects with Alagille Syndrome

          2. Ability to understand and willingness to sign informed consent/assent prior to
             initiation of any study procedures.

        Exclusion Criteria:

          1. Experienced an adverse event or serious adverse event related to the study drug
             during a core LUM001 treatment protocol that led to the discontinuation of the
             subject from the core LUM001 treatment study

          2. History of non-adherence during the subject's participation in the core LUM001
             treatment protocol.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Dorenbaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lumena Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Barbat</last_name>
    <phone>858-461-0694</phone>
    <email>info@lumenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Lloyd</last_name>
      <email>carla.lloyd@bch.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Fazeelat Sharif</last_name>
      <email>fazeelat.sharif@bch.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Deidre Kelly, FRCPI, FRCP,FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Balatoni</last_name>
      <email>nicola.balatoni@leedsth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Patricia McClean, MD,FRCP,FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palaniswamy Karthikeyan</last_name>
      <email>pkarthikeyan@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Denise Holley</last_name>
      <email>denise.holley@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Alastair Baker, MBChB,FFARCS,MRCP,FRCPCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.lumenapharma.com</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Alagille Syndrome</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
